Immunogénicité et faisabilité de la vaccination intradermique contre la rage au Québec

Objectifs : La vaccination en préexposition contre la rage est recommandée aux personnes exposées au virus dans le cadre du travail ainsi qu’à certains voyageurs. Avec un coût d’au moins 150$ par dose par voie intramusculaire (IM), cette recommandation est peu suivie. Au Canada, le Comité consultatif national de l’immunisation et le Comité d’immunisation du Québec permettent l’usage de la voie intradermique (ID) qui est une alternative plus économique en utilisant 1/10 de la dose IM, pourvu que certaines conditions soient respectées. Cette étude a pour but d’évaluer la faisabilité et l’immunogénicité de la vaccination en préexposition par voie ID.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-03-05

• Fields of study

  Not labeled

• Identifiers
  DOI 10.14745/CCDR.V41I03A03F
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of Potentially Rabid Animal Exposure among Foreign Travelers in Southeast Asia

  2012cited by this paper
• Rabies surveillance in the United States during 2011.

  2012cited by this paper
• Bat rabies in the United States and Canada from 1950 through 2007: human cases with and without bat contact.

  2008cited by this paper
• Survival After Treatment of Rabies With Induction of Coma

  2007cited by this paper
• Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine.

  2007cited by this paper
• Immunogenicity study of abbreviated rabies preexposure vaccination schedules.

  2007cited by this paper
• Pre-exposure rabies booster vaccinations: a literature review.

  2006cited by this paper
• Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children.

  2006cited by this paper
• The effectiveness of intradermal pre-exposure rabies vaccination in an Australian travel medicine clinic.

  2006cited by this paper
• Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers".

  2006cited by this paper
• Intradermal pre-exposure rabies immunisation in New Zealand.

  2006cited by this paper
• Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.

  2006cited by this paper
• Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals.

  2005cited by this paper
• Rabies update for travel medicine advisors.

  2003cited by this paper
• Public Health Impact of Reemergence of Rabies, New York

  2002cited by this paper
• Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination.

  1999cited by this paper
• Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.

  1998cited by this paper
• Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations.

  1997cited by this paper
• Should travellers in rabies endemic areas receive pre-exposure rabies immunization?

  1994cited by this paper
• Immunization with a human diploid cell strain of rabies virus vaccine: two-year results.

  1978cited by this paper

• No citing papers are available for this paper.